Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes GBR 830, which is in Phase 2b clinical trails for the treatment of atopic dermatitis; GRC 27864 that is in Phase 2b clinical trails for the treatment of osteoarthritic pain; and GRC 17536, which has completed Phase 2a clinical trails for the treatment of painful diabetic neuropathy. The company’s products pipeline comprises GBR 1302, which is in Phase 1a/1b clinical trails for the treatment of breast cancer; and GBR 1342 that is in Phase 1a/1b clinical trails for the oncology; GRC 5xxxx, a MAP4K1 inhibitor compound, which is in pre-clinical studies for the treatment of cancer; and Ryaltris for allergic rhinitis. The company was founded in 1977 and is based in Mumbai, India.